Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

10,936 total articles

Okta Is Breaking Out on AI Identity Demand - Buy, But Scale In

Okta Is Breaking Out on AI Identity Demand - Buy, But Scale In

Okta's recent quarterly beat and AI-driven bookings momentum validate the cybersecurity identity narrative. The stock is in a technical breakout, but the valuation is priced for growth. Buy on a disciplined entry with a clear stop and mid-term target while monitoring conversion of bookings into recurring revenue and competitive pressure.

AT&T: Buy the Accretion Trade — Small M&A, Clearer Growth Path

AT&T: Buy the Accretion Trade — Small M&A, Clearer Growth Path

AT&T's latest acquisitions and bolt-on integrations have produced incremental revenue and margin lift that the market has mostly underappreciated. The business still faces legacy headwinds, but near-term catalysts and an attractive yield create a favorable risk/reward for a swing trade. Entry $17.50, target $20.50, stop $16.00.

IREN: Buy the AI Scarcity Repricing After a Panic Pullback

IREN: Buy the AI Scarcity Repricing After a Panic Pullback

IREN just got cheaper after a 15% pullback following an earnings miss. The company controls renewable-rich capacity, has secured multibillion-dollar contracts and is already delivering AI compute to hyperscalers. This trade targets a re-rating as deployments accelerate and short interest unwinds — with a clearly defined entry, stop and target for a…

Tilray Poised For Another Short-Squeeze Run - Tactical Long Idea

Tilray Poised For Another Short-Squeeze Run - Tactical Long Idea

Tilray (TLRY) carries meaningful short exposure (roughly 18.4M shares short, ~13.8% of float) against a float of 133.2M and multi-million average daily volume. With positive top-line momentum in FY2026, constructive consumer beverage and distribution news, and technicals sitting near short-term support, the stock looks set for a volatile upside mov…

Nexans: Buy the Dip While the Street Prices a Pause

Nexans: Buy the Dip While the Street Prices a Pause

Nexans looks like a classic 'plateau before payoff' setup: near-term volumes and margins appear constrained, but backlog composition and exposure to grid modernization create a high-conviction mid-term asymmetric trade. Enter on weakness, use a tight stop, and target re-rating as project awards and margin recovery show through.

AXT Pullback Creates a Speculative Entry: Upgrade to Buy

AXT Pullback Creates a Speculative Entry: Upgrade to Buy

AXT's share-price correction after an extraordinary rally and a dilutive follow-on offering has created a measurable risk-reward for speculative, mid-horizon traders. The business controls the lion's share of the indium phosphide substrate market and stands to benefit from structural AI data center demand, but valuation remains extreme and executio…

Buy Genius Sports Now: Growth Beats the Leverage Headwind

Buy Genius Sports Now: Growth Beats the Leverage Headwind

Genius Sports is trading at an attractive forward multiple after accelerating revenue and EBITDA, a strategically accretive acquisition, and growing addressable markets for sports data and betting. Rising leverage is real, but manageable against improving cash flow and near-term catalysts. This trade idea outlines an entry at $8.015, a $12.00 targe…

MARA: Play the Bitcoin Beta with a Conditional AI Upside

MARA: Play the Bitcoin Beta with a Conditional AI Upside

Marathon Digital remains primarily a bitcoin-mining story with a nascent AI/infrastructure angle. This trade buys a pullback to get bitcoin exposure with a defined stop, sized for traders who want asymmetric upside if BTC and Marathon’s AI initiatives both accelerate over the next 180 trading days.

Buy Verastem: Rare-disease Revenues Fund a KRAS G12D Growth Option

Buy Verastem: Rare-disease Revenues Fund a KRAS G12D Growth Option

Verastem's rare-disease commercial foothold is providing non-dilutive funding and credibility at a time the company needs to advance its KRAS G12D platform. The balance sheet and operational runway are imperfect, but the combination of a revenue stream, manageable enterprise value ($599M), and concentrated short interest creates an asymmetric risk/…